| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Tnni3 |
| Uniprot No | P48787 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-211aa |
| 氨基酸序列 | ADESSDAAGEPQPAPAPVRRRSSANYRAYATEPHAKKKSKISASRKLQLKTLMLQIAKQEMEREAEERRGEKGRVLRTRCQPLELDGLGFEELQDLCRQLHARVDKVDEERYDVEAKVTKNITEIADLTQKIYDLRGKFKRPTLRRVRISADAMMQALLGTRAKESLDLRAHLKQVKKEDIEKENREVGDWRKNIDALSGMEGRKKKFEG |
| 预测分子量 | 24.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Tnni3重组蛋白的模拟参考文献示例(基于常见研究方向，非真实文献)：
---
1. **文献名称**：Recombinant Tnni3 Expression and Purification in Escherichia coli
**作者**：Chen L, et al.
**摘要**：研究报道了通过大肠杆菌表达系统高效表达和纯化重组人源Tnni3蛋白，优化了诱导条件与层析方法，获得了高纯度蛋白用于后续抗体开发及功能研究。
---
2. **文献名称**：Functional Analysis of Tnni3 Mutants in Cardiac Hypertrophy Models
**作者**：Wang H, et al.
**摘要**：通过构建Tnni3重组蛋白的磷酸化位点突变体，研究其在心肌细胞收缩调控中的作用，发现特定位点突变可抑制病理性心肌肥厚信号通路。
---
3. **文献名称**：Tnni3 Recombinant Protein Improves Cardiac Function in Ischemia-Reperfusion Injury
**作者**：Suzuki K, et al.
**摘要**：在小鼠模型中验证外源性重组Tnni3蛋白的治疗潜力，发现其通过调节钙离子敏感性减轻缺血再灌注损伤后的心肌功能障碍。
---
4. **文献名称**：Structural Insights into Tnni3 Interaction with Tropomyosin
**作者**：Zhang Y, et al.
**摘要**：利用重组Tnni3蛋白进行X射线晶体学研究，解析其与肌钙蛋白复合物的结合界面，揭示了Tnni3在心肌收缩中的分子调控机制。
---
**注意**：以上为模拟示例，实际文献需通过PubMed/Google Scholar检索(关键词：*Tnni3 recombinant protein*)。建议结合具体研究领域(如疾病机制、结构生物学等)进一步筛选。
**Background of Recombinant Tnni3 Protein**
Troponin I3 (Tnni3), a key component of the cardiac troponin complex, is a sarcomeric protein critical for regulating muscle contraction in the heart. It is encoded by the *TNNI3* gene and specifically expressed in cardiac tissue, distinguishing it from skeletal muscle isoforms (Tnni1 and Tnni2). The troponin complex, comprising Tnni3 (inhibitory subunit), Tnnt2 (troponin T), and TnC (troponin C), modulates calcium-dependent interactions between actin and myosin filaments during the cardiac cycle. Tnni3 binds to actin in a calcium-sensitive manner, inhibiting actomyosin ATPase activity during diastole. Dysregulation of Tnni3 is linked to cardiomyopathies, including hypertrophic cardiomyopathy (HCM) and restrictive cardiomyopathy (RCM), often due to mutations affecting calcium sensitivity or protein stability.
Recombinant Tnni3 protein is produced via genetic engineering, typically using bacterial (e.g., *E. coli*) or mammalian expression systems to ensure proper folding and post-translational modifications. Its production enables *in vitro* studies to dissect cardiac contraction mechanisms, screen therapeutic compounds, or develop diagnostic assays. For instance, recombinant Tnni3 serves as a standard in immunoassays measuring cardiac troponin I (cTnI) levels, a gold-standard biomarker for myocardial infarction. Additionally, it aids in structural studies (e.g., X-ray crystallography) to map mutation-induced conformational changes or design targeted drugs.
Research using recombinant Tnni3 has advanced understanding of heart disease pathophysiology and spurred innovations in cardiac biomarker detection. Its clinical relevance underscores its role in both diagnostic applications and therapeutic development, particularly for precision medicine approaches targeting inherited cardiomyopathies.
×
